Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy

Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming and Ghassan El-Haddad
Journal of Nuclear Medicine January 2021, 62 (1) 69-72; DOI: https://doi.org/10.2967/jnumed.120.242875
Jonathan R. Strosberg
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taymeyah Al-Toubah
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleonora Pellè
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
2Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnna Smith
3Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mintallah Haider
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tai Hutchinson
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason B. Fleming
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghassan El-Haddad
3Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    (A) Maximum-intensity projection demonstrates peritoneal carcinomatosis (arrow) and liver and mediastinal metastases in patient with progressive metastatic small-bowel NET. (B–D) Axial 68Ga-DOTATATE PET (B), attenuation-correction CT (C), and 68Ga-DOTATATE PET/CT (D) demonstrate uptake in extensive peritoneal metastatic implants (arrows).

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Axial 68Ga-DOTATATE PET (A), attenuation-correction CT (B), and 68Ga-DOTATATE PET/CT (C) demonstrate somatostatin-receptor–expressive mesenteric (arrows) and peritoneal (arrowheads) metastases. There is mild tethering of loops of bowel to mesenteric mass in right lower quadrant (arrows).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Coronal contrast-enhanced CT of abdomen and pelvis demonstrates small-bowel obstruction with dilated loops of bowel tethered to mesenteric lesion (arrow).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Axial 68Ga-DOTATATE PET (A), attenuation-correction CT (B), and 68Ga-DOTATATE PET/CT (C) demonstrate somatostatin-receptor–expressive peritoneal carcinomatosis (arrows), including peritoneal lesions along anastomotic suture line (arrowheads).

Tables

  • Figures
    • View popup
    TABLE 1

    Patient Characteristics and Clinical Course

    Patient no.177Lu-DOTATATE administrationBowel-obstruction time pointInterventionOutcome
    1Without steroids1 wk after treatment 11: steroidsTreatment was discontinued; patient died 6 mo after treatment 1
    1 mo after treatment 12: surgical intervention, steroids
    2With steroids2 wk after treatment 11: steroidsPatient remains on total parenteral nutrition
    3 wk after treatment 42: surgical intervention attempted (aborted); steroids
    3 mo after treatment 43: total parenteral nutrition
    31 and 2: without steroids5 wk after treatment 3Steroids initially; major surgical abdominal debulking 5 mo after obstructionPatient recovering from surgery and doing well
    3: with steroids
    4With steroids3 mo after treatment 2Treatment canceled; patient died 6 mo after treatment 2
    6 mo after treatment 2
    5Without steroids10 d after treatment 2SteroidsPatient recovered; future treatment delayed until further workup
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (1)
Journal of Nuclear Medicine
Vol. 62, Issue 1
January 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming, Ghassan El-Haddad
Journal of Nuclear Medicine Jan 2021, 62 (1) 69-72; DOI: 10.2967/jnumed.120.242875

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming, Ghassan El-Haddad
Journal of Nuclear Medicine Jan 2021, 62 (1) 69-72; DOI: 10.2967/jnumed.120.242875
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Consensus Guideline for the Management of Peritoneal Metastases in Patients with Neuroendocrine Neoplasms
  • Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients
  • Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
  • Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy
  • Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical

  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
  • Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
Show more Clinical

Similar Articles

Keywords

  • 177Lu-DOTATATE
  • peptide receptor radionuclide therapy
  • bowel obstruction
  • intestinal obstruction
SNMMI

© 2025 SNMMI

Powered by HighWire